{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:59:18Z","timestamp":1790326758332,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr. Diabetes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this case-control study was to assess the efficacy of dapagliflozin combined with metformin for type-2 diabetes mellitus (T2DM) with obstructive sleep apnea hypopnea syndrome (OSAHS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 36 patients with newly-diagnosed T2DM and OSAHS were randomized divided into two groups. Eighteen OSAHS patients with T2DM, who were treated with dapagliflozin and metformin, were assigned as the dapagliflozin group. These patients were given dapagliflozin and metformin for 24 weeks between February 2017 and February 2018. Another 18 OSAHS patients with T2DM, who were treated with glimepiride and metformin for 24 weeks, were assigned as the control group. Fasting plasma glucose (FPG) level, postprandial blood glucose (PPG), hemoglobin A1C (HbA1c), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), blood lipids, body mass index (BMI), blood pressure, apnea-hypopnea index (AHI), minimum oxygen saturation (LSpO\n                      <jats:sub>2<\/jats:sub>\n                      ), and Epworth Somnolence Scale (ESS) score were measured before and at 24 weeks after the initiation of treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the dapagliflozin group, triglyceride (TG), systolic pressure (SBP) and diastolic pressure (DBP) significantly decreased following treatment, while high-density lipoprotein cholesterol (HDL-C) significantly increased (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Furthermore, a reduction in AHI, an increase in LSpO\n                      <jats:sub>2<\/jats:sub>\n                      and a decrease in ESS score were observed in the dapagliflozin group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), but not in the control group. Moreover, blood glucose, HbA1c, HOMA-IR, and BMI significantly decreased in these two groups, and the decrease was more significant in the dapagliflozin group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These present results indicate that dapagliflozin can significantly reduce glucose, BMI, blood pressure and AHI, and improve hypoxemia during sleep and excessive daytime sleepiness, which thereby has potential as an effective treatment approach for OSAHS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41387-019-0098-5","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T10:03:15Z","timestamp":1572861795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study"],"prefix":"10.1038","volume":"9","author":[{"given":"Yi","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong-Lan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"98_CR1","first-page":"471","volume":"161","author":"A Qaseem","year":"2014","unstructured":"Qaseem, A. et al. Clinical Guidelines Committee of the American College of Physicians. Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from theAmerican College of Physicians. Ann. Intern. Med. 161, 471\u2013483 (2014).","journal-title":"Ann. Intern. Med."},{"key":"98_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.smrv.2012.08.002","volume":"17","author":"H Tuomilehto","year":"2013","unstructured":"Tuomilehto, H., Sepp\u00e4, J. & Uusitupa, M. Obesity and obstructive sleep apnea-clinical significance of weight loss. Sleep Med. Rev. 17, 321 (2013).","journal-title":"Sleep Med. Rev."},{"key":"98_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/MCP.0b013e3283659da5","volume":"19","author":"AA Tahrani","year":"2013","unstructured":"Tahrani, A. A., Ali, A. & Stevens, M. J. Obstructive sleep apnoea and diabetes: an update. Curr. Opin. Pulmon. Med. 19, 631\u2013638 (2013).","journal-title":"Curr. Opin. Pulmon. Med."},{"key":"98_CR4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2337\/dc08-1776","volume":"32","author":"GD Foster","year":"2009","unstructured":"Foster, G. D. et al. Sleep AHEAD Research Group. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 32, 1017\u20131019 (2009).","journal-title":"Diabetes Care"},{"key":"98_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/pcad.1999.0410367","volume":"41","author":"JW Weiss","year":"1999","unstructured":"Weiss, J. W., Launois, S. H., Anand, A. & Garpestad, E. Cardiovascular morbidity in obstructive sleep apnea. Prog. Cardiovasc. Dis. 41, 367\u2013376 (1999).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"98_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jjcc.2013.08.009","volume":"63","author":"JS Floras","year":"2014","unstructured":"Floras, J. S. Sleep apnea and cardiovascular risk. J. Cardiol. 63, 3\u20138 (2014).","journal-title":"J. Cardiol."},{"key":"98_CR7","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1161\/CIRCRESAHA.118.310783","volume":"122","author":"JS Floras","year":"2018","unstructured":"Floras, J. S. Sleep apnea and cardiovascular disease: an enigmatic risk factor. Circ. Res. 122, 1741\u20131764 (2018).","journal-title":"Circ. Res."},{"key":"98_CR8","first-page":"471","volume":"161","author":"N Listed","year":"2014","unstructured":"Listed, N. Summaries for patients: diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 161, 471\u2013U94 (2014).","journal-title":"Ann. Intern. Med."},{"key":"98_CR9","first-page":"104","volume":"31","author":"DR Cal","year":"2017","unstructured":"Cal, D. R., De, V. N. & van Wagensveld, B. A. Obstructive sleep apnea and bariatric surgical guidelines: summary and update. Curr. Opin. Anaesthesiol. 31, 104 (2017).","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"98_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"LA Gallo","year":"2015","unstructured":"Gallo, L. A., Wright, E. M. & Vallon, V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab. Vasc. Dis. Res. 12, 78\u201389 (2015).","journal-title":"Diab. Vasc. Dis. Res."},{"key":"98_CR11","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1210\/jc.2014-3472","volume":"100","author":"A Merovci","year":"2015","unstructured":"Merovci, A. et al. Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function. J. Clin Endocrinol. Metab. 100, 1927\u20131932 (2015).","journal-title":"J. Clin Endocrinol. Metab."},{"key":"98_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2015.02.009","volume":"754","author":"Y Hayashizaki-Someya","year":"2015","unstructured":"Hayashizaki-Someya, Y. et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l -amino acid-defined diet in rats. Eur. J. Pharmacol. 754, 19\u201324 (2015).","journal-title":"Eur. J. Pharmacol."},{"key":"98_CR13","first-page":"4573","volume":"23","author":"I Gouniberthold","year":"2017","unstructured":"Gouniberthold, I., Hanssen, R., Ravarani, L. & Berthold, H. K. Management of blood pressure and heart rate in patients with diabetes mellitus. Curr. Pharm. Design 23, 4573\u20134582 (2017).","journal-title":"Curr. Pharm. Design"},{"key":"98_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4158\/CS-2017-0153","volume":"24","author":"AJ Garber","year":"2018","unstructured":"Garber, A. J.2018 AACE T2D Algorithm Authors Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142018. Endocr. Pract. 24(), 91\u2013120 (2018).","journal-title":"Endocr. Pract."},{"key":"98_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/MED.0000000000000095","volume":"21","author":"SK Malin","year":"2014","unstructured":"Malin, S. K. & Kashyap, S. R. Effects of metformin on weight loss: potential mechanisms. Curr. Opin. Endocrinol. Diabetes Obes. 21, 323\u2013329 (2014).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"98_CR16","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2337\/dc11-1299","volume":"35","author":"TDPP Group","year":"2012","unstructured":"Group, T. D. P. P. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 35, 731\u2013737 (2012).","journal-title":"Diabetes Care"},{"key":"98_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1085-8","volume":"16","author":"J Wilding","year":"2018","unstructured":"Wilding, J. et al. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Med. 16, 116 (2018).","journal-title":"BMC Med."},{"key":"98_CR18","doi-asserted-by":"publisher","first-page":"821A","DOI":"10.1378\/chest.1117017","volume":"140","author":"A Kabir","year":"2011","unstructured":"Kabir, A. Effect of metformin on the severity of obstructive sleep apnea in patients with diabetes mellitus (Type 2). Chest 140, 821A\u2013821A (2011).","journal-title":"Chest"},{"key":"98_CR19","unstructured":"Lin, D., Rein, L., Tarima, S., Woodson, B. T., Meurer, J. R. The relationship between metformin and obstructive sleep apnea. J. Sleep Med. Disord. 2, pii: 1027 (2015)."},{"key":"98_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/HJH.0000000000000047","volume":"32","author":"T Kasai","year":"2014","unstructured":"Kasai, T., Bradley, T. D., Friedman, O. & Logan, A. G. Effect of intensified diuretic therapy on overnight rostral fluid shift and obstructive sleep apnoea in patients with uncontrolled hypertension. J. Hypertension 32, 673 (2014).","journal-title":"J. Hypertension"},{"key":"98_CR21","doi-asserted-by":"crossref","unstructured":"White, L. H., Bradley, T. D. & Logan, A. G. Pathogenesis of obstructive sleep apnoea in hypertensive patients: role of fluid retention and nocturnal rostral fluid shift. J. Hum. Hypertens. 29, 342\u2013350 (2015).","DOI":"10.1038\/jhh.2014.94"},{"issue":"08","key":"98_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.5664\/jcsm.6054","volume":"12","author":"Kiran Khurshid","year":"2016","unstructured":"Khurshid, K. et al. Effect of antihypertensive medications on the severity of obstructive sleep apnea: a systematic review and meta-analysis. J. Clin. Sleep Med. 12, 1143\u20131151(2016).","journal-title":"Journal of Clinical Sleep Medicine"},{"key":"98_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-0699-9","volume":"16","author":"CZ Fiori","year":"2015","unstructured":"Fiori, C. Z., Martinez, D., Gon\u00e7alves, S. C., Montanari, C. C. & Fuchs, F. D. Effect of diuretics and sodium-restricted diet on sleep apnea severity: study protocol for a randomized controlled trial. Trials 16, 188 (2015).","journal-title":"Trials"},{"key":"98_CR24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/jhh.2009.96","volume":"24","author":"K Gaddam","year":"2010","unstructured":"Gaddam, K. et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J. Hum. Hypertens. 24, 532 (2010).","journal-title":"J. Hum. Hypertens."},{"key":"98_CR25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3109\/10641963.2015.1131290","volume":"38","author":"L Yang","year":"2016","unstructured":"Yang, L. et al. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin. Exp. Hypertens. 38, 464\u2013468 (2016).","journal-title":"Clin. Exp. Hypertens."},{"key":"98_CR26","doi-asserted-by":"crossref","unstructured":"Eskandari, D., Zou, D., Grote, L., Hoff, E. & Hedner, J. Acetazolamide reduces blood pressure and sleep-disordered breathing in patients with hypertension and obstructive sleep apnea: a Randomized Controlled Trial. J. Clin. Sleep Med. 14, 309\u2013317 (2018).","DOI":"10.5664\/jcsm.6968"},{"key":"98_CR27","doi-asserted-by":"crossref","unstructured":"Yadollahi, A., Vena, D., Lyons, O. D. & Bradley, T. D. Relationship of fluid accumulation in the neck to sleep structure in men during daytime sleep. J. Clin. Sleep Med. 12, 1365\u20131371 (2016).","DOI":"10.5664\/jcsm.6190"},{"key":"98_CR28","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder, J. et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 97, 1020\u20131031 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"98_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","volume":"87","author":"H Tobita","year":"2017","unstructured":"Tobita, H., Sato, S., Miyake, T., Ishihara, S. & Kinoshita, Y. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr. Ther. Res. Clin. Exp. 87, 13\u201319 (2017).","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"98_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197342","volume":"13","author":"NT Economou","year":"2018","unstructured":"Economou, N. T. et al. Sleepiness, fatigue, anxiety and depression in chronic obstructive pulmonary disease and obstructive sleep apnea\u2014overlap\u2014syndrome, before and after continuous positive airways pressure therapy. PLoS One 13, e0197342 (2018).","journal-title":"PLoS One"},{"key":"98_CR31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/0091217417696737","volume":"51","author":"YY Li","year":"2016","unstructured":"Li, Y. Y. et al. Anxiety and depression are improved by continuous positive airway pressure treatments in obstructive sleep apnea. Int. J. Psychiatry Med. 51, 554 (2016).","journal-title":"Int. J. Psychiatry Med."},{"key":"98_CR32","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/lary.24729","volume":"124","author":"SL Ishman","year":"2014","unstructured":"Ishman, S. L. et al. Does surgery for obstructive sleep apnea improve depression and sleepiness? Laryngoscope 124, 2829\u20132836 (2014).","journal-title":"Laryngoscope"},{"key":"98_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.smrv.2015.07.002","volume":"8","author":"MA Gupta","year":"2016","unstructured":"Gupta, M. A., Simpson, F. C. & Lyons, D. C. The effect of treating obstructive sleep apnea with positive airway pressure on depression and other subjective symptoms: a systematic review and meta-analysis. Sleep Med. Rev. 8, 55\u201368 (2016).","journal-title":"Sleep Med. Rev."},{"key":"98_CR34","first-page":"1","volume":"15","author":"M Devita","year":"2017","unstructured":"Devita, M. et al. Obstructive sleep apnea and its controversial effects on cognition. J. Clin. Exp. Neuropsychol. 15, 1 (2017).","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"98_CR35","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1513\/AnnalsATS.201802-121OC","volume":"15","author":"GR Geovanini","year":"2018","unstructured":"Geovanini, G. R. et al. Association between obstructive sleep apnea and cardiovascular risk factors: variation by age, sex, and race. The Multi-Ethnic Study of Atherosclerosis. Ann. Am. Thorac. Soc. 15, 970\u2013977 (2018).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"98_CR36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1183\/09031936.00198810","volume":"38","author":"M Gasa","year":"2011","unstructured":"Gasa, M. et al. Obstructive sleep apnoea and metabolic impairment in severe obesity. Eur. Respir. J. 38, 1089\u20131097 (2011).","journal-title":"Eur. Respir. J."},{"key":"98_CR37","doi-asserted-by":"crossref","unstructured":"Gohil, A. & Hannon, T. S. Poor sleep and obesity: concurrent epidemics in adolescent youth. Front. Endocrinol. 9, 364 (2018).","DOI":"10.3389\/fendo.2018.00364"},{"key":"98_CR38","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1007\/s11695-018-3403-9","volume":"28","author":"AC de Assun\u00e7\u00e3o Machado","year":"2018","unstructured":"de Assun\u00e7\u00e3o Machado, A. C., da Silva, A. M. V., Signori, L. U., da Costa Alvarez, G. & Mottin, C. C. Endothelial function of patients with morbid obesity submitted to Roux-en-Y gastric bypass with and without obstructive sleep apnea-hypopnea syndrome. Obes. Surg. 28, 3595\u20133603 (2018).","journal-title":"Obes. Surg."},{"key":"98_CR39","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1183\/09031936.00099710","volume":"37","author":"WJ Randerath","year":"2011","unstructured":"Randerath, W. J. et al. European Respiratory Society task force on non-CPAP therapies in sleep apnoea. Non-CPAP therapies in obstructive sleep apnoea. Eur. Respir. J. 37, 1000\u20131028 (2011).","journal-title":"Eur. Respir. J."},{"key":"98_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/sleep\/32.5.623","volume":"32","author":"I Villar","year":"2009","unstructured":"Villar, I., Izuel, M., Carrizo, S., Vicente, E. & Marin, J. M. Medication adherence and persistence in severe obstructive sleep apnea. Sleep 32, 623\u2013628 (2009).","journal-title":"Sleep"},{"key":"98_CR41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.7326\/0003-4819-159-11-201312030-00009","volume":"159","author":"A Qaseem","year":"2013","unstructured":"Qaseem, A. et al. Clinical Guidelines Committee of the American College of Physicians. Clinical Guidelines Committee of the American College of Physicians. Management ofobstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 159, 471\u2013483 (2013).","journal-title":"Ann. Intern. Med."}],"container-title":["Nutrition &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41387-019-0098-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-019-0098-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-019-0098-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T09:52:20Z","timestamp":1671184340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41387-019-0098-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["98"],"URL":"https:\/\/doi.org\/10.1038\/s41387-019-0098-5","relation":{},"ISSN":["2044-4052"],"issn-type":[{"value":"2044-4052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"9 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"32"}}